☆ 4.5 Article

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

NATURE CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Towards a population-based threshold of protection for COVID-19 vaccines

David Goldblatt et al.

Summary: This study measured immune responses to four COVID-19 vaccines and found a significant correlation between IgG anti-Spike antibodies and neutralization of the virus, as well as protection against infection. The protective threshold for each vaccine was calculated, providing a potential method for evaluating the efficacy of new vaccines.

VACCINE (2022)

添加到收藏夹

Article Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor et al.

Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Letter Oncology

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Duncan R. McKenzie et al.

CANCER CELL (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors

Ithai Waldhorn et al.

Summary: This study found that the pattern of immunogenicity, efficacy, and safety of BNT162b2 vaccine in patients with cancer with solid tumors at six months postvaccination resembles that of the general population, and the vaccine has shown favorable short-term profile in cancer patients.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Sean H. Lim et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Annika Fendler et al.

Summary: Patients with cancer have higher morbidity and mortality when infected with COVID-19. The CAPTURE study found that while most patients had immune responses against the original SARS-CoV-2, neutralizing antibody titers against variants were significantly reduced, with some patients experiencing a decrease in antibody levels. However, neutralizing antibody titers remained stable for some patients.

NATURE CANCER (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions

Francesca Arruga et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Renhong Yan et al.

SCIENCE (2020)

添加到收藏夹

Article Hematology

Guidelines on the use of irradiated blood components

Theodora Foukaneli et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

添加到收藏夹

Article Virology

Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2

Marina Johnson et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

添加到收藏夹

Article Oncology

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

R. Marcus et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

Anna H. Turaj et al.

CANCER CELL (2017)

添加到收藏夹

Article Hematology

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

Alan G. Ramsay et al.

BLOOD (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.